Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Cybin Inc CYBN


Primary Symbol: N.CYBN

Healthcare Drug Manufacturers - Specialty & Generic
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary... see more

Bullboard (NEO:CYBN)

View:
Prev ... 21
Comment by CBDANDMEon Nov 12, 2020 1:09pm

RE:I like it

Also pretty low float!
69
Discussion
Post by 88guy88on Nov 12, 2020 12:11pm

I like it

Raised 45 million pre public market.....so nicely cashed up.....phase 2 trials in ealy 2021 only a couple of months away....focus on sublingual dose so it has more immediate effect rather than pill ...more  
780
Discussion
Post by superzoomer710on Nov 12, 2020 10:47am

why is this .89

Can anyone tell me what Cybiin has??????????
726
Comment by realitycheck00on Nov 11, 2020 12:09am

RE:RE:RE:Shrim

I beleive around 130m from the last deck I saw.
62
Discussion
Comment by pp19888on Nov 10, 2020 4:24pm

RE:RE:Shrim

Added today, was expecting to open 2 but when I seen under a dollar went all in. 
66
Discussion
Comment by CBDANDMEon Nov 10, 2020 3:25pm

RE:RE:Shrim

How many outstanding shares in this company. 60 mill?
44
Discussion
Comment by realitycheck00on Nov 10, 2020 3:21pm

RE:Shrim

$45M raised on pre-public!  Not too shabby - nice little warchest for M&A
60
Discussion
Post by TheTanManon Nov 10, 2020 1:47pm

Shrim

Schwing
92
Discussion
Comment by EDMINNEMAon Nov 06, 2020 9:23am

RE:A big scandal might be unfolding in Canadian markets

THERE ARE HUGE SCANDALS IN EVERY MARKET, OTC MARKETS IN THE USA THE WORSE
101
Discussion
Post by SHeditorialon Sep 30, 2020 1:06pm

Early-stage psychedelics market is exploding...

And only going up... https://stockhouse.com/news/newswire/2020/09/29/this-company-illustrates-exactly-why-psilocybin-market-exploding
76
Post by SHeditorialon Sep 29, 2020 6:56pm

'Mushrooming' sector and opportunity

https://stockhouse.com/opinion/interviews/2020/09/22/a-psychedelic-nutraceutical-opportunity-a-boost-for-brain-and-your-portfolio
70
Post by SHeditorialon Sep 23, 2020 5:56pm

Enter the psychedelics play with a quickness

https://stockhouse.com/opinion/interviews/2020/09/22/a-psychedelic-nutraceutical-opportunity-a-boost-for-brain-and-your-portfolio
80
Prev ... 21
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities